Fludarabine phosphate in chronic lymphoproliferative diseases. The French Group on CLL.

J L Binet

Index: Nouv. Rev. Fr. Hematol. 35(1) , 5-7, (1993)

Full Text: HTML

Abstract

The review of Phase II trials in patients treated by Fludarabine phosphate (Fludara I.V) has been demonstrated to have unequivocal benefit for some patients with Chronic Lymphocytic Leukemia (CLL) non Hodgkin lymphoma and macroglobulinemia. Comparison of Fludara I.V with other treatment regimens is now studied in randomised protocols for B and C stages of CLL.

Related Compounds

  • Fludarabine phosph...

Related Articles:

Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration.

2015-01-01

[Cancer Chemother. Pharmacol. 75(1) , 67-75, (2015)]

Fludarabine phosphate in lymphoma: an important new therapeutic agent.

1996-01-01

[Cancer Treat. Res. 85 , 3-14, (1996)]

Fludarabine phosphate in the treatment of chronic lymphocytic leukemia: biology, clinical impact, and future directions.

1993-01-01

[Cancer Treat. Res. 64 , 105-19, (1993)]

Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies.

1991-01-01

[J. Clin. Oncol. 9(1) , 175-88, (1991)]

Metabolism and action of fludarabine phosphate.

1990-10-01

[Semin. Oncol. 17(5 Suppl 8) , 3-17, (1990)]

More Articles...